SETD2 and systemic mastocytosis: Martinelli et al. reported a loss of function mutations of SETD2 in 53 SM patients and suggested that reduced SETD2 expression/absence might potentiate the effects of KIT constitutive activation to determine the phenotype of AdvSM [17].